Radiopharm Theranostics Limited

RAD

AU0000181851

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:13 2024-06-28 EDT			5-day change	1st Jan Change
0.038 ^AUD	-7.32%		+11.76%	-48.65%

06-25	Radiopharm Theranostics Raises AU$70 Million to Fund Clinical Programs; Shares Jump 24%	MT
06-20	US Radiopharmaceutical Firm to Invest Up to AU$18 Million into Radiopharm Theranostics	MT

Radiopharm Theranostics Limited announced that it has received AUD 7.481259 million in funding from Lantheus Holdings, Inc.

June 19, 2024

Radiopharm Theranostics Limited announced a private placement of 149,625,180 common shares at a price of AUD 0.05 per share for the gross proceeds of CAD 7,481,259 on June 20, 2024. The transaction included participation from new investor, Lantheus Holdings, Inc.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	LANTHEUS HOLDINGS, INC.	80.29 USD	-1.25%	+1.50%	5.57B
	RADIOPHARM THERANOSTICS LIMITED	0.038 AUD	-7.32%	+11.76%	11.67M

Latest news about Radiopharm Theranostics Limited

Radiopharm Theranostics Raises AU$70 Million to Fund Clinical Programs; Shares Jump 24%	06-24	MT
US Radiopharmaceutical Firm to Invest Up to AU$18 Million into Radiopharm Theranostics	06-19	MT
Radiopharm Theranostics Limited announced that it has received AUD 7.481259 million in funding from Lantheus Holdings, Inc.	06-19	CI
Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	05-08	MT
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	02-29	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate	02-20	MT
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%	02-06	MT
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement	01-23	MT
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	12-26	MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	12-25	MT
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer	12-08	MT
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	11-24	CI
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	11-24	CI
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	11-20	MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	23-10-17	MT
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%	23-10-08	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	23-05-29	MT
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	23-05-09	CI
Radiopharm Theranostics Receives US FDA Orphan Drug Designation for Pancreatic Cancer Medication	23-05-09	MT
Radiopharm Theranostics Receives AU$1.6 Million R&D Tax Refund; Shares Fall 3%	23-03-27	MT
Radiopharm Theranostics, GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia	23-03-26	MT
Radiopharm Theranostics Limited and GenesisCare to Develop Novel Radiopharmaceuticals	23-03-26	CI
Radiopharm Theranostics Appoints Dr. Ken Herrmann to the Scientific Advisory Board	23-03-03	CI

Chart Radiopharm Theranostics Limited

Duration

Period

More charts

Company Profile

Radiopharm Theranostics Limited is an Australia-based clinical-stage company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. It has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

Sector

Pharmaceuticals

Calendar

2024-07-02 - Investor Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Radiopharm Theranostics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0254 USD

Average target price

0.334 USD

Spread / Average Target

+1,217.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RADIOPHARM THERANOSTICS LIMITED	-48.65%	11.67M
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals